Sanofi/$SNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
$SNY
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
82,878
ISIN
US80105N1054
Website
Sanofi Metrics
BasicAdvanced
$118B
8.09
$5.91
0.48
$1.60
3.34%
Price and volume
Market cap
$118B
Beta
0.48
52-week high
$60.12
52-week low
$45.80
Average daily volume
2.2M
Dividend rate
$1.60
Financial strength
Total debt to equity
23.008
Interest coverage (TTM)
17.14%
Profitability
EBITDA (TTM)
14,239.278
Gross margin (TTM)
70.96%
Net profit margin (TTM)
13.95%
Operating margin (TTM)
20.80%
Effective tax rate (TTM)
20.10%
Revenue per employee (TTM)
$632,960
Management effectiveness
Valuation
Price to earnings (TTM)
8.093
Price to revenue (TTM)
1.128
Price to book
1.33
Price to tangible book (TTM)
5.21
Dividend yield (TTM)
3.34%
Forward dividend yield
3.34%
Growth
Revenue change (TTM)
-2.42%
Earnings per share change (TTM)
39.56%
3-year revenue growth (CAGR)
3.84%
10-year revenue growth (CAGR)
2.56%
3-year earnings per share growth (CAGR)
-1.65%
10-year earnings per share growth (CAGR)
4.46%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Sanofi's planned acquisition of U.S. biotech firm Blueprint Medicines for up to $9.5 billion aims to diversify its portfolio and reduce dependence on Dupixent, potentially enhancing long-term growth prospects. (reuters.com)
The company's strong first-quarter performance, with a 20.1% rise in business operating income driven by robust sales of Dupixent and newer products like Beyfortus, indicates solid financial health and effective product development. (reuters.com)
Sanofi's plan to buy back 5 billion euros in shares and its commitment to increased acquisition activity following the anticipated sale of its stake in the consumer health unit, Opella, demonstrate a strategic focus on enhancing shareholder value and expanding its pharmaceutical portfolio. (reuters.com)
The failure of itepekimab's Phase 3 COPD trial removes a key growth prospect and highlights Sanofi's reliance on Dupixent, raising concerns about the company's future growth and diversification. (seekingalpha.com)
Sanofi's dependence on Dupixent, which is poised to lose exclusivity in the early 2030s, could lead to significant revenue declines if not offset by successful new product launches. (reuters.com)
Potential new tariffs on pharmaceuticals by the U.S. administration could lead to supply shortages and limited patient access, posing risks to Sanofi's profitability and market presence in the U.S. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 26 Jun 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Sanofi News
AllArticlesVideos
Press release: Availability of the Q2 2025 Aide mémoire
GlobeNewsWire·1 day ago
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
GlobeNewsWire·1 day ago
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SNY) has a market cap of $118B as of July 01, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SNY) stock is 8.09 as of July 01, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SNY) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is $1.59864 and the yield is 3.34%. Sanofi has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SNY) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SNY) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.